Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com
New Developments Warrant Rethinking HCC Transplant Criteria

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock
Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

April 29th 2025

senior scientist | Image credit: Ohio State University
Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

This Week in Managed Care: February 9, 2018
February 9th 2018

This Week in Managed Care: February 9, 2018

This week, the top managed care stories included Indiana being approved as the second state to implement work requirements in Medicaid; research found 5-year survival rates for cancer are increasing; coverage from the American Society of Clinical Oncology's 2018 Genitourinary Symposium.
Site Logo
February 9th 2018

Is There Evidence for Local Treatment for Newly Diagnosed Metastatic Prostate Cancer?

Jaime Rosenberg
During a session at the 2018 Genitourinary Cancers Symposium, 2 doctors debate whether there is existing evidence for local treatment for patients newly diagnosed with metastatic disease.
Dr Joe O'Sullivan on Molecular Therapies in Prostate Cancer
February 9th 2018

Dr Joe O'Sullivan on Molecular Therapies in Prostate Cancer

For the first time, molecular therapies, such as radium-223, provide a survival-prolonging agent for men with advanced prostate cancer affecting the bone, explained Joe O'Sullivan, MD, FRCR, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast.
Site Logo
February 9th 2018

Osteomimicry May Contribute to Uptake of Radium-223 Within Bone Metastases for Patients With mCRPC

Jaime Rosenberg
Osteomimicry may contribute to the uptake of radium-223 within bone metastases and may subsequently enhance the therapeutic benefit of radium-223, according to an abstract presented by Andrew Armstrong, MD, associate professor of medicine, Duke University School of Medicine, at the 2018 Genitourinary Cancers Symposium.
Site Logo
February 9th 2018

Apalutamide Significantly Improved Metastasis-Free Survival in Men With nmCRPC

Jaime Rosenberg
Apalutamide significantly improved median metastasis-free survival by 2 years in men with nonmetastatic castrate-resistant prostate cancer (nmCRPC), according to study results presented by Eric Jay Small, MD, MD, FASCO, chief of the division of hematology and oncology in the department of medicine at the University of California, San Francisco (UCSF), deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center, and professor in residence in the Department of Medicine and Department of Urology, at the 2018 Genitourinary Cancers Symposium.
Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival
February 9th 2018

Long-Term Follow-Up of CAR T in ALL Indicates Early Treatment Extends Survival

Laura Joszt, MA
A long-term follow-up analyzing the toxic effects and results from a phase 1 clinical trial of adult patients with relapsed B-cell acute lymphoblastic leukemia (ALL) who were treated with CD19-specific chimeric antigen receptor (CAR) T cells found patients with low disease burden had a longer medial overall survival and a lower incidence of toxicity.
Atezolizumab Treatment Safe and Effective in Metastatic Urothelial Cancer Patients
February 8th 2018

Atezolizumab Treatment Safe and Effective in Metastatic Urothelial Cancer Patients

Kaitlynn Ely
Patients with metastatic urothelial cancer treated with atezolizumab monotherapy demonstrated tolerability for the drug and general ability to manage adverse effects, according to a study published in JAMA Oncology.
ACCC Survey Recognizes Major Challenges Cancer Centers Experience
February 8th 2018

ACCC Survey Recognizes Major Challenges Cancer Centers Experience

Kaitlynn Ely
While an increasing number of immunotherapies are reaching market and becoming available, cancer centers feel unprepared to prescribe these treatments and handle adverse events and side effects, according to findings from a new survey from the Association of Community Cancer Centers.
Terrill Jordan on Implementing OCM: Take It Step by Step
February 6th 2018

Terrill Jordan on Implementing OCM: Take It Step by Step

Before undertaking something like implementing the Oncology Care Model, practices should understand the scope of the project and the overall importance it can have for patient care, said Terrill Jordan, CEO of Regional Cancer Care Associates.
Cancer Mortality Statistics and Disparities in the US: Dr Patricia Salber Interviews Dr Otis Brawley
February 6th 2018

Cancer Mortality Statistics and Disparities in the US: Dr Patricia Salber Interviews Dr Otis Brawley

There has been some good news regarding cancer: a decline in the death rate and in new cancer diagnoses for men. However, the latest findings also highlight what still needs to be worked on, according to Otis W. Brawley, MD, MACP, FASCO, FACE, chief medical and scientific officer for the American Cancer Society.
Dr Peter Aran Discusses Year 1 Feedback on OCM
February 5th 2018

Dr Peter Aran Discusses Year 1 Feedback on OCM

When you have constant evolving contract, there are changes, and so some of the feedback I’m getting is that sometimes it’s hard to keep up with the changes, said Peter Aran, MD, medical director of Population Health Management at Blue Cross Blue Shield of Oklahoma.
Dr Adam Brufsky: Choosing a Therapy for Breast Cancer Patients
February 4th 2018

Dr Adam Brufsky: Choosing a Therapy for Breast Cancer Patients

There are a number of treatment choices available to treat patients with breast cancer and diagnostic tests can assist in the decision making, according to Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh.
5-Year Survival Rates for Patients With Cancer Worldwide
February 4th 2018

5-Year Survival Rates for Patients With Cancer Worldwide

Jaime Rosenberg
CONCORD-3 includes the records of 37.5 million patients diagnosed with cancer from 2000 to 2014, 322 population-based cancer registries in 71 countries and territories, and data on patients' vital status at least 5 years following diagnosis.
Podcast: This Week in Managed Care—State of the Union and Other Health News
February 3rd 2018

Podcast: This Week in Managed Care—State of the Union and Other Health News

Laura Joszt, MA
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: February 2, 2018
February 2nd 2018

This Week in Managed Care: February 2, 2018

This week, the top managed care news included President Donald Trump vowing to lower drug prices during his State of the Union address; 3 corporate giants joined forces on healthcare; and CAR T-cell therapy was named the cancer advance of the year.
AJMC® in the Press, February 2, 2018
February 2nd 2018

AJMC® in the Press, February 2, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Site Logo
February 2nd 2018

Quality of Life

Researchers at the 59th Annual Meeting and Exposition of the American Society of Hematology in Atlanta, Georgia presented studies investigating the quality of life associated with various oncologic diseases.
New Study Analyzes Need for Biopsies During Follow-Up Care in Breast Cancer
February 2nd 2018

New Study Analyzes Need for Biopsies During Follow-Up Care in Breast Cancer

Kaitlynn Ely
New research on breast cancer biopsies and counseling after treatment will allow surgeons to have more meaningful conversations with their patients, according to a study published in JAMA Surgery.
Site Logo
February 2nd 2018

Cost of Care

Various presenters at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia discussed the cost of care involved in several different cancer treatments.
Site Logo
February 1st 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Ibrutinib Is More Effective Than Stem-Cell Transplant in Patients With Form of Chronic Leukemia

Jaime Rosenberg
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
E-Cigarette Smoke Poses Threat to DNA Repair Activity
February 1st 2018

E-Cigarette Smoke Poses Threat to DNA Repair Activity

Kaitlynn Ely
E-cigarette smokers have a high risk of developing lung and bladder cancer, as well as certain heart diseases due to carcinogenic e-cigarette smoke (ECS), according to a study published in the Proceedings of the National Academy of Sciences.
Site Logo
February 1st 2018

Treatment-Free Remission and Preventing Cardiotoxicity: The Future of CML Care

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Clonal Expansion and Aging Fuel the Development of Neoplasms, Say Experts at ASH

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

AJMC®tv Interviews, January 2018

At the American Society of Hematology’s 59th Annual Meeting and Exposition, healthcare industry leaders sat down with The American Journal of Managed Care® to speak about what’s new and important about changes in healthcare. Access the video clips at ajmc.com/conferences/ash-2017.
Site Logo
February 1st 2018

Single-Agent Ibrutinib Promising in MCL and CLL, Improves Patient Well-Being

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
February 1st 2018

Biosimilars Update

Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Site Logo
January 31st 2018

CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients

Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
Study Shows Interactive Tool Increases Patient Knowledge of Breast Cancer Treatment Options
January 31st 2018

Study Shows Interactive Tool Increases Patient Knowledge of Breast Cancer Treatment Options

Samantha DiGrande
The Cancer Surveillance and Outcomes Research Team at the University of Michigan Comprehensive Cancer Center recently developed an interactive online tool to help patients with breast cancer understand their treatment options more fully.
Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development
January 31st 2018

Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development

Providers should be involved in new reimbursement model development from day 1, said Roger Brito, DO, national director for oncology, Aetna.
<1
...
555657585960616263
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo